Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 43 min ago
Peer-reviewedCC BY-NC-SA 4.0Clinical and Experimental Hepatology

Dietary interventions in metabolic dysfunction-associated steatotic liver disease: current evidence, research priorities, and clinical translation

  1. 1Department of Environmental Medicine, Poznan University of Medical Sciences, Poznan, Poland
  2. 2Collegium Medicum of Jan Kochanowski University, Kielce, Poland
  3. 3Department of Infectious Diseases and Hepatology, Medical University of Silesia, Katowice, Poland

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) is closely linked to excess adiposity, insulin resistance, and adverse dietary patterns. Dietary management is a potentially disease-modifying component of care, but no single standardized “MASLD diet” applies to all patients. This narrative review evaluates energy restriction, Mediterranean-style eating, low-carbohydrate, ketogenic, dietary approaches to stop hypertension (DASH), intermittent fasting, vegetarian, and plant-based approaches, together with practical food-based recommendations. The strongest evidence supports improved dietary quality and, in patients with excess body weight, a sustainable energy deficit that produces clinically meaningful weight loss. Mediterranean-style eating remains the best-supported named pattern, although evidence is stronger for liver fat and cardiometabolic outcomes than for histological or clinical liver outcomes. Management should prioritize minimally processed, predominantly plant-based, fiber-rich foods and unsaturated fats while limiting sugar-sweetened beverages, refined carbohydrates, ultra-processed foods, red and processed meat, and alcohol. Normal-weight MASLD, cirrhosis, and incretin-associated weight loss require individualized goals emphasizing metabolic control, nutritional adequacy, and muscle preservation.

Related

  1. Omics-based Decoding of Metabolic Dysfunction-associated Fatty Liver Disease: From Pathogenesis to Clinical Translation
    Jinyang Zhai, Yan Lu, Jian-Gao Fan
    Journal of Clinical and Translational HepatologyPeer-reviewedCC BY-NCFull textGeneral medicineEurope PMC
  2. Omics-derived signatures in metabolic dysfunction-associated steatotic liver disease: from molecular characterization to clinical translation.
    Ziyang Qin, Dulguun Juramt, Yuguo Chen +5
    Frontiers in medicinePeer-reviewedCC BYFull textEpidemiology & public healthEurope PMCPMC
  3. Effectiveness of eHealth lifestyle interventions on management of metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis.
    Yangguo Zhao, Xinrui Yang, Yang Bai +2
    Nutrition & diabetesPeer-reviewedCC BY-NC-NDFull textEpidemiology & public healthEurope PMCDOAJ
  4. Mobile application-enabled lifestyle interventions for metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis
    Caroline Gosson, Maria Megapanou, Sarah White +1
    BMJ Open GastroenterologyPeer-reviewedCC BY-NC 4.0Full textEpidemiology & public healthPMC
  5. Efficacy and safety of GLP-1 receptor agonists in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) : A systematic review and meta-analysis
    Mohammed Alfawaz, Dareen Bajamaan, Lama Alghamdi +7
    MedicinePeer-reviewedCC BYFull textGeneral medicineEurope PMC
BibTeX
@article{choreziak2026dietary,
  title = {{Dietary interventions in metabolic dysfunction-associated steatotic liver disease: current evidence, research priorities, and clinical translation}},
  author = {Anna Choręziak and Piotr Rzymski and Barbara Poniedziałek and Krystyna Dobrowolska and Michał Brzdęk and Jerzy Jaroszewicz and Dorota Zarębska-Michaluk},
  journal = {Clinical and Experimental Hepatology},
  year = {2026},
  month = sep,
  doi = {10.5114/ceh.2026.164368},
  url = {https://doi.org/10.5114/ceh.2026.164368},
  note = {CC BY-NC-SA 4.0},
}
RIS
TY  - JOUR
TI  - Dietary interventions in metabolic dysfunction-associated steatotic liver disease: current evidence, research priorities, and clinical translation
AU  - Anna Choręziak
AU  - Piotr Rzymski
AU  - Barbara Poniedziałek
AU  - Krystyna Dobrowolska
AU  - Michał Brzdęk
AU  - Jerzy Jaroszewicz
AU  - Dorota Zarębska-Michaluk
PY  - 2026
DA  - 2026/09/08
JO  - Clinical and Experimental Hepatology
DO  - 10.5114/ceh.2026.164368
UR  - https://doi.org/10.5114/ceh.2026.164368
AB  - Metabolic dysfunction-associated steatotic liver disease (MASLD) is closely linked to excess adiposity, insulin resistance, and adverse dietary patterns. Dietary management is a potentially disease-modifying component of care, but no single standardized “MASLD diet” applies to all patients. This narrative review evaluates energy restriction, Mediterranean-style eating, low-carbohydrate, ketogenic, dietary approaches to stop hypertension (DASH), intermittent fasting, vegetarian, and plant-based approaches, together with practical food-based recommendations. The strongest evidence supports improved dietary quality and, in patients with excess body weight, a sustainable energy deficit that produces clinically meaningful weight loss. Mediterranean-style eating remains the best-supported named pattern, although evidence is stronger for liver fat and cardiometabolic outcomes than for histological or clinical liver outcomes. Management should prioritize minimally processed, predominantly plant-based, fiber-rich foods and unsaturated fats while limiting sugar-sweetened beverages, refined carbohydrates, ultra-processed foods, red and processed meat, and alcohol. Normal-weight MASLD, cirrhosis, and incretin-associated weight loss require individualized goals emphasizing metabolic control, nutritional adequacy, and muscle preservation.
SN  - 2392-1099
SN  - 2449-8238
ER  -